Aminergic Phytocannabinoids Derivatives as Multi-Target Agents for Neurological Disorders
Summary
The University of South Carolina has filed patent application US20260108541A1 with the USPTO for aminergic phytocannabinoid derivatives as multi-target agents for treating neurological disorders in mammals including humans. The application covers CBD derivatives functionalized at position 7 and THC derivatives functionalized at position 11. Inventors are Juan Francisco Leon Oyola and Zachary I. Stryker.
“Compounds, methods of making the compounds, and methods of using the compounds to treat neurological disorders in mammals, including humans.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The University of South Carolina has filed patent application US20260108541A1 with the USPTO for aminergic phytocannabinoid derivatives as multi-target agents for treating neurological disorders in mammals including humans. The application specifically covers CBD derivatives functionalized at position 7 of the CBD molecule and THC derivatives functionalized at position 11 of the THC molecule.
Entities developing cannabinoid-based neurological therapies should monitor this published application as potential prior art affecting freedom-to-operate analyses for related compounds.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
AMINERGIC PHYTOCANNABINOIDS DERIVATIVES AS MULTI-TARGET AGENTS FOR NEUROLOGICAL DISORDERS
Application US20260108541A1 Kind: A1 Apr 23, 2026
Assignee
University of South Carolina
Inventors
Juan Francisco Leon Oyola, Zachary I. Stryker
Abstract
Compounds, methods of making the compounds, and methods of using the compounds to treat neurological disorders in mammals, including humans. The compounds are aminergic phytocannabinoid derivatives, including cannabinoid (CBD) derivatives functionalized at position 7 of the CBD molecule and tetrahydrocannabinol (THC) derivatives functionalized at position 11 of the THC molecule.
CPC Classifications
A61K 31/658 A61P 25/00 C07C 217/74
Filing Date
2025-10-22
Application No.
19365329
Named provisions
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.